Ultralight | $9,300,000 | (Apr 21, 2026)
Sage Haven | $3,000,000 | (Apr 21, 2026)
CREAO AI | $10,000,000 | (Apr 21, 2026)
Certified by Founder
Lodge
Shinobi Therapeutics
start up
United States
- South San Francisco, CA
- 13/12/2023
- Series A
- $51,000,000
Shinobi Therapeutics is developing a new class of hypoimmune CD8ab iPS-T cells for cancer and beyond by using immune evasion to unlock the full potential of iPSCs.
- Industry Biotechnology Research
- Website https://www.shinobitx.com/
- LinkedIn https://www.linkedin.com/company/shinobitx/about/
Related People
Dan KempFounder
United States -
New York City Metropolitan Area
Accomplished BioPharma Executive with experience in drug discovery (Novartis), translational and clinical development (Merck), sell-side, buy-side and M&A transactional BD (Takeda), Executive oversight (GammaDelta Therapeutics, Adaptate Therapeutics) and Operational Leadership (Cell Therapies at Takeda).
ViewsML | $4,900,000 | (Apr 21, 2026)
Antioch | $8,500,000 | (Apr 21, 2026)
Wavelet Medical | $7,000,000 | (Apr 21, 2026)
Rivan Industries | $34,000,000 | (Apr 21, 2026)
urfuture | $2,299,785 | (Apr 21, 2026)
TraqCheck | $8,000,000 | (Apr 21, 2026)
Giggles | $1,000,000 | (Apr 21, 2026)
brainjo GmbH | $2,356,020 | (Apr 21, 2026)
Coral(US) | $12,500,000 | (Apr 21, 2026)